PLEKHA4 Inhibitors
PLEKHA4 inhibitors are a diverse group of chemical compounds that indirectly decrease the functional activity of PLEKHA4 through various mechanisms within specific cellular signaling pathways. For example, compounds like Ly294002 and Wortmannin directly target PI3K, an enzyme upstream of PLEKHA4 in the PI3K/AKT signaling pathway. Inhibition of PI3K leads to a reduction in AKT phosphorylation and prevents the activation of downstream signaling components, including PLEKHA4, thereby diminishing its activity. Compounds such as Rapamycin and PP242 exert their effects on PLEKHA4 by inhibiting the mTOR pathway, which is a central conduit for cellular growth and metabolism signals that PLEKHA4 is likely implicated in. The inhibition of mTOR reduces signaling through pathways in which PLEKHA4 may act, leading to decreased PLEKHA4 activity.
Other compounds like Palbociclib, U0126, and PD98059 influence cell cycle progression and MAPK signaling, respectively. By halting the cell cycle or inhibiting specific kinases within the MAPK pathway, these drugs can indirectly affect PLEKHA4's activity. Since PLEKHA4 might be involved in processes that are active at particular stages of the cell cycle or within certain signaling pathways, the use of these inhibitors can lead to a decrease in PLEKHA4 activity by limiting the cellular context in which PLEKHA4 functions.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A potent inhibitor of phosphoinositide 3-kinases (PI3Ks). PLEKHA4 is implicated in PI3K signaling. By inhibiting PI3K, Ly294002 prevents the formation of PIP3, thus inhibiting AKT phosphorylation and activation. As PLEKHA4 is involved in PI3K-mediated signaling, the inhibition of PI3K can decrease PLEKHA4's functional activity indirectly. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Another potent and irreversible inhibitor of PI3K. Similar to Ly294002, Wortmannin binds to the p110 subunit of PI3K, preventing PIP3 formation. This inhibition reduces AKT activation which is upstream of PLEKHA4, thereby indirectly inhibiting PLEKHA4's function within the signaling cascade. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor that can indirectly affect PLEKHA4 activity by inhibiting downstream signaling pathways that PLEKHA4 may be involved in. As mTOR is a downstream effector of PI3K, inhibiting mTOR with Rapamycin can decrease the functional activity of PLEKHA4 in the PI3K/AKT/mTOR pathway. | ||||||
PP242 | 1092351-67-1 | sc-301606A sc-301606 | 1 mg 5 mg | $56.00 $169.00 | 8 | |
A selective inhibitor of mTOR kinase. Unlike Rapamycin, which is an allosteric inhibitor, PP242 directly inhibits both mTORC1 and mTORC2 complexes. This comprehensive inhibition can reduce PLEKHA4 activity by attenuating signaling pathways where PLEKHA4 functions downstream of mTOR. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
A CDK4/6 inhibitor that arrests the cell cycle in the G1 phase. PLEKHA4, associated with cellular proliferation signals, could have its activity diminished as a result of cell cycle arrest, given that its function may be tied to specific cell cycle stages. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
A selective inhibitor of MEK, which also works by inhibiting the ERK/MAPK pathway. Similar to U0126, PD98059 can lead to reduced PLEKHA4 activity due to decreased signaling through the ERK/MAPK pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of c-Jun N-terminal kinase (JNK), which may influence PLEKHA4 activity by altering stress response and apoptosis signaling pathways. As JNK can be upstream of signaling processes involving PLEKHA4, its inhibition can lead to decreased PLEKHA4 activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A selective inhibitor of p38 MAPK, which could reduce PLEKHA4 activity by inhibiting inflammatory signaling pathways where PLEKHA4 might function. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
A proteasome inhibitor that can lead to the accumulation of polyubiquitinated proteins and disrupt various signaling pathways. This disruption can indirectly inhibit PLEKHA4 activity by affecting its proteostasis and interactions. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
A tyrosine kinase inhibitor that can indirectly inhibit PLEKHA4 by inhibiting various receptors and downstream signaling pathways, potentially including those where PLEKHA4 is active. | ||||||